Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Roche
Industry Sector: HealthTechnology
CEO: Thomas Schinecker, PhD
Number Of Employees: 103,249
Enterprise Value: $253,038,563,830
PE Ratio: 28.56
Exchange/Ticker 1: SIX:ROG
Exchange/Ticker 2: OTCQB:RHHBY
Latest Market Cap: $267,665,683,767
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Mar 27, 2025
Data Byte
Immunology takeouts led by IgA nephropathy, IBD
Seven of 11 $1B+ immunology acquisitions focused on two diseases
BioCentury | Mar 24, 2025
Data Byte
Petrelintide up front shatters biotech deal record
At nearly $1.7B, Zealand got $300M more than the prior top cash payment
BioCentury | Mar 20, 2025
Data Byte
FDA’s new and supplemental approvals in February
Springworks gets priority review voucher for Gomekli, first NovoLog biosimilar reaches market, and more
BioCentury | Mar 19, 2025
Product Development
Tempus aims for precision in complexity
With clinical records, patient samples and images in the millions, the diagnostics and data company is betting precision medicine can go multimodal
BioCentury | Mar 18, 2025
Finance
Strategics back Sofinnova Partners’ ‘pan-European’ accelerator in €165M fund
Following eight-year ‘pilot experiment’ in Italy, the firm’s Biovelocita now builds companies across Europe
BioCentury | Mar 17, 2025
Deals
AZ acquires cell therapy play Esobiotech, Taiho acquires ADC partner Araris: Deals Report
Plus: Roche partners with Zealand, AZ with Alteogen and more
BioCentury | Mar 15, 2025
Data Byte
VEGF ophthalmic sales: Vabysmo gains ground, biosimilars struggle to take off
Eylea remains market leader as Roche’s grows its share of AMD pie; biosimilars still a rounding error
BioCentury | Mar 12, 2025
Deals
Chasing amylin: Must-have obesity target key to Roche-Zealand deal
Swiss pharma pays $1.7B upfront for Zealand’s petrelintide, adding obesity’s hottest target
BioCentury | Mar 7, 2025
Product Development
Could amylin outshine GLP-1 in obesity?
If the preclinical data translate to the clinic, amylin has a good chance to supplant GLP-1 for the overweight to moderate obesity population
Items per page:
1 - 10 of 12591